Point72 Hong Kong’s Elicio Therapeutics ELTX Stock Holding History

Point72 Hong Kong’s Portfolio ELTX Stock Details ELTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-188	Closed	-$5K	–	1978
2021 Q4	$5K	Buy	+188	New	+$9.51K	﹤0.01%	1729

Other funds holding ELTX

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

LSAG

Lake Street Advisors Group Portsmouth, New Hampshire $2.17B AUM 16.99% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Point72 Hong Kong's ELTX Position: Q1 2022 in Review

Point72 Hong Kong sold out of Elicio Therapeutics (ELTX) in Q1 2022, closing a stake of 188 shares — an estimated $5K sold.

Point72 Hong Kong first reported a position in ELTX in Q4 2021 and held it in 1 quarter. The position peaked at $5K in Q4 2021. 47 funds tracked by Wall St. Rank hold ELTX as of Q1 2022.

Point72 Hong Kong reported no remaining Elicio Therapeutics position as of Q1 2022 after selling out during the quarter.
Point72 Hong Kong sold 188 Elicio Therapeutics shares in Q1 2022, an estimated $5K.
Point72 Hong Kong first reported a position in Elicio Therapeutics in Q4 2021 and held it in 1 quarter.
Point72 Hong Kong's Elicio Therapeutics position peaked at $5K in Q4 2021.
47 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q1 2022.

Based on Point72 Hong Kong's 13F filing for Q1 2022, filed 16 May 2022.